North East and North Cumbria
ICS Formulary
ICS Formulary
6 Endocrine system
06-01-02-03 SGL2 inhibitors
| Dapagliflozin |
|
First Choice
|
5mg and 10mg tablets Approved for treatment of:
For details on use in Cardiovascular disease, please see entry in 02.15
|
 NICE TA288: Dapagliflozin in combination therapy for treating type 2 diabetes NICE TA390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes NICE TA418: Dapagliflozin in triple therapy for treating type 2 diabetes NICE TA1075: Dapagliflozin for treating chronic kidney disease |
|
| Canagliflozin |
|
Formulary
|
|
|
NICE TA315: Canagliflozin for type 2 diabetes NICE TA390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes |
|
|
| Empagliflozin |
|
Formulary
|
|
|
NICE NG18: Diabetes (type 1 and type 2) in children and young people: diagnosis and management NICE TA336: Empagliflozin for type 2 diabetes NICE TA390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes NICE TA942: Empagliflozin for treating chronic kidney disease |
|
|
| Ertugliflozin |
|
Formulary
|
|
|
NICE TA572: Ertugliflozin as monotherapy or with metformin for treating type 2 diabetes NICE TA583: Ertugliflozin with metformin and a dipeptidyl peptidase-4 inhibitor for treating type 2 diabetes |
|
|
| Dapagliflozin combination products |
|
Non Formulary
|
Dapagliflozin / metformin: 5mg/1g and 5mg/850mg Dapagliflozin / saxagliptin: 10mg/5mg
|
|
Links
HWTO Patient Prioritisation Guideline- HWTO Patient Prioritisation Guideline
- MHRA Drug Safety Update (January 2025): GLP-1 and dual GIP/GLP-1 receptor agonists: potential risk of pulmonary aspiration during general anaesthesia or deep sedation
- MHRA Drug Safety Update (January 2026): GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists: strengthened warnings on acute pancreatitis, including necrotising and fatal cases
- MHRA Drug Safety Update (Jun 2019): GLP-1 receptor agonists: reports of diabetic ketoacidosis when concomitant insulin was rapidly reduced or discontinued
- MHRA Drug Safety Update (October 2024) : GLP-1 receptor agonists: reminder of the potential side effects and to be aware of the potential for misuse
- MHRA Drug Safety Updates: SGLT2 inhibitors
- MHRA DSU: Falsified Mounjaro KwikPen 15mg pre-filled pens, Feb 2026
- MHRA DSU: Semaglutide (Wegovy, Ozempic and Rybelsus): risk of Non-arteritic Anterior Ischemic Optic Neuropathy (NAION), Feb 2026
- National Patient Safety Alert - Shortage of GLP-1 receptor agonists (GLP-1 RA) update
- National Patient Safety Alert - Shortage of GLP-1 receptor agonists (GLP-1 RA) update
- NICE NG 28: Type 2 diabetes in adults: management
- NICE NG17: Type 1 diabetes in adults: diagnosis and management
- NICE NG18: Diabetes (type 1 and type 2) in children and young people: diagnosis and management
- NICE NG18: Diabetes (type 1 and type 2) in children and young people: diagnosis and management
- NICE NG18: Diabetes (type 1 and type 2) in children and young people: diagnosis and management
- NICE NG18: Diabetes (type 1 and type 2) in children and young people: diagnosis and management
- NICE NG19: Diabetic foot problems: prevention and management
- NICE NG28: Type 2 diabetes in adults: management
- NICE NG3: Diabetes in pregnancy: management from preconception to the postnatal period
- NICE TA1026: Tirzepatide for managing overweight and obesity
- NICE TA1075: Dapagliflozin for treating chronic kidney disease
- NICE TA1075: Dapagliflozin for treating chronic kidney disease
- NICE TA248: MR exenatide
- NICE TA288: Dapagliflozin in combination therapy for treating type 2 diabetes
- NICE TA288: Dapagliflozin in combination therapy for treating type 2 diabetes
- NICE TA315: Canagliflozin for type 2 diabetes
- NICE TA336: Empagliflozin for type 2 diabetes
- NICE TA390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes
- NICE TA390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes
- NICE TA390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes
- NICE TA390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes
- NICE TA418: Dapagliflozin in triple therapy for treating type 2 diabetes
- NICE TA418: Dapagliflozin in triple therapy for treating type 2 diabetes
- NICE TA572: Ertugliflozin as monotherapy or with metformin for treating type 2 diabetes
- NICE TA583: Ertugliflozin with metformin and a dipeptidyl peptidase-4 inhibitor for treating type 2 diabetes
- NICE TA622: Sotagliflozin with insulin for treating type 1 diabetes
- NICE TA664: Liraglutide for managing overweight and obesity
- NICE TA875: Semaglutide for managing overweight and obesity
- NICE TA875: Semaglutide for managing overweight and obesity
- NICE TA924: Tirzepatide for treating type 2 diabetes
- NICE TA942: Empagliflozin for treating chronic kidney disease
- North East and North Cumbria ICS - Medication Management of Type 2 Diabetes in Adults Guidelines
- North East Guideline For Use Of Sodium Glucose Co transporter 2 Inhibitors (SGLT2i)
- NTAG Endocrine System Recommendations
- NTAG Treatment Appraisal: Oral semaglutide for the treatment of type 2 diabetes mellitus.
- Tier 3 Weight Management Commissioning Statement